Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
ObsEva Announces Progress On Cost Reduction Initiatives And Stay Of Moratorium Proceedings
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7 million of accounts
ObsEva Announces Progress On Cost Reduction Initiatives, Stay of Moratorium Proceedings
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program
Reported Early Thursday, ObsEva Announces IND Approval For Yuyuan Bioscience’s Phase 1 Clinical Trial Of Nolasiban To Improve Clinical Pregnancy And Live Birth Rates In Women Undergoing In Vitro Fertilization In China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – October 13, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company developing novel
Why Vicinity Motor Is Trading Higher By Over 65%; Here Are 26 Stocks Moving Premarket
Gainers
Vicinity Motor Corp. (NASDAQ: VEV) rose 65.4% to $1.72 in pre-market trading. Vicinity Motor started deliveries of the first Class 3 electric truck to roll off the assembly line in Canada.
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday’s Mid-Day Session
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split.
Why Nutanix Is Trading Higher By 16%; Here Are 33 Stocks Moving Premarket
Gainers
Bright Green Corporation (NASDAQ: BGXX) shares rose 63.8% to $2.26 in pre-market trading after gaining around 33% on Wednesday.
Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.